PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Cromoglicate→

Cromoglicate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
16110-51-3
Molecular formula
C23H16O11
Molecular weight
468.4 g/mol
Drug class
Mast-cell stabiliseranti-allergic agent (cromoglicic acid)
Mechanism of action
Inhibits activation and mediator release from sensitised mast cells and other inflammatory cells. The precise molecular mechanism is not fully established; it acts prophylactically and is not a rapid bronchodilator. Sodium cromoglicate is a salt of the same active moiety.
Indications / reported uses
  • Prevention of bronchial asthma symptoms with inhaled formulations
  • Treatment or prevention of allergic rhinitis with nasal formulations
  • Relief of allergic conjunctivitis with ophthalmic formulations
  • Selected systemic use for mastocytosis with oral formulations; use is route- and product-specific

Sources: US DailyMed — Cromolyn sodium products · NHS — Sodium cromoglicate · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Cromoglicate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cromoglicate Permitted Daily Exposure (PDE) report (the Cromoglicate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cromoglicate Occupational Exposure Limit (OEL) report (the Cromoglicate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.